Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Pt. 1 Of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Dunsire takes stock of Millennium's business development mandate as part of a global organization, its clinical pipeline and other operational changes since the firm became the Takeda Oncology company.
Advertisement

Related Content

Back To School: Catch Up On Our Executive Interviews
Back To School: Catch Up On Our Executive Interviews
Standing Alone While Standing Together: A Conversation With Millennium CEO Dunsire (Pt. 2 Of 2)
Standing Alone While Standing Together: A Conversation With Millennium CEO Dunsire (Pt. 2 Of 2)
Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition

Topics

Advertisement
UsernamePublicRestriction

Register

PS069741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel